报告预览

强生（JOHNSON & JOHNSON）2024年第二季度业绩报告（英文版）（23页）.pdf

编号：170857

PDF 中文版 PPTX 23页 3.58MB 下载积分：VIP专享

下载报告请您先登录！

强生（JOHNSON & JOHNSON）2024年第二季度业绩报告（英文版）（23页）.pdf

1、 =AchievedPOTENTIAL APPROVALS US/EUPLANNED SUBMISSIONS US/EUPOTENTIAL CLINICAL DATASum of Check ChangeSum of Check ChangeSum of Check ChangePhase IIIOPSUMIT(macitentan)USOPSUMIT(macitentan)USSIMPONI(golimumab)P P TREMFYA(guselkumab)EUPediatric Pulmonary Arterial Hypertension(TOMORROW)Pediatric Pulmo

2、nary Arterial Hypertension(TOMORROW)EUPediatric Ulcerative ColitisCrohns Disease(GALAXI)P PUSOPSYNVI(macitentan/tadalafil STCT)UPTRAVI(selexipag)STELARA(ustekinumab)P P TREMFYA(guselkumab)EUPulmonary Arterial HypertensionP PEUPediatric Pulmonary Arterial Hypertension(SALTO)P PEUPediatric Crohns Dise

3、aseUlcerative Colitis Monotherapy(QUASAR)P PUSEDURANT(rilpivirine)REKAMBYSUSTREMFYA(guselkumab)P P RYBREVANT(amivantamab)EUHIV pediatric 2-12 year oldP PEUHIV AdolescentsPediatric PsoriasisSubcutaneous(PALOMA-3)P PUSBALVERSA(erdafitinib)USnipocalimabP PUSTREMFYA(guselkumab)ERLEADA(apalutamide)EUUrot

4、helial Cancer(THOR)EUGeneralized Myasthenia GravisP PEUCrohns Disease(GALAXI)High Risk Prostate Cancer(PROTEUS)USDARZALEX(daratumumab)USSPRAVATO(esketamine)monotherapyUSTREMFYA(guselkumab)P P seltorexantFrontline multiple myeloma transplant eligible(PERSEUS)Treatment Resistant Depression(TRD4005)Ped

5、iatric Juvenile Psoriatic ArthritisAdjunctive treatment for major depressive disorder with insomnia symptomsP PUSCARVYKTI(ciltacabtagene autoleucel)P PUSRYBREVANT(amivantamab)P PUSTREMFYA(guselkumab)P P nipocalimabP PEURelapsed Refractory multiple myeloma w/1-3 PL(CARTITUDE-4)P PEUSubcutaneous(PALOM

6、A-3)P PEUUlcerative Colitis Monotherapy(QUASAR)Generalized Myasthenia GravisP PUSRYBREVANT(amivantamab)P PUSDARZALEX(daratumumab)USTREMFYA(guselkumab)TREMFYA(guselkumab)P PEUFrontline Non Small Cell Lung Cancer in combination with chemotherapy(PAPILLON)P PEUFrontline multiple myeloma transplant elig

7、ible(PERSEUS)Ulcerative Colitis Subcutaneous Induction(ASTRO)Crohns Disease Subcutaneous Induction(GRAVITI)USRYBREVANT/lazertinibP PUSTREMFYA(guselkumab)aticaprantEUNon Small Cell Lung Cancer 2L(MARIPOSA-2)P PEUCrohns Disease Subcutaneous Induction(GRAVITI)Adjunctive Major Depressive Disorder(VENTUR

8、A 1)USRYBREVANT/lazertinibP P SPRAVATO(esketamine)monotherapyEUNon Small Cell Lung Cancer(MARIPOSA)Treatment Resistant Depression(TRD4005)DARZALEX(daratumumab)Amyloidosis(ANDROMEDA)Phase IIJNJ-4804 Co-antibody TherapeuticPsoriatic Arthritis(AFFINITY)P P nipocalimabSjogrens Disease(DAHLIAS)TAR-200(RI

9、S/gemcitabine plus cetrelimab)Non Muscle Invasive Bladder Cancer(SunRISe-1)Johnson&Johnson Innovative Medicine PipelineKey Events in 2024*This information is as of July 17,2024 to the best of the Companys knowledge.Johnson&Johnson assumes no obligation to update this information.BALVERSA US Full Approval

友情提示

1、下载报告失败解决办法
2、PDF文件下载后，可能会被浏览器默认打开，此种情况可以点击浏览器菜单，保存网页到桌面，就可以正常下载了。
3、本站不支持迅雷下载，请使用电脑自带的IE浏览器，或者360浏览器、谷歌浏览器下载即可。
4、本站报告下载后的文档和图纸-无水印,预览文档经过压缩，下载后原文更清晰。

本文（强生（JOHNSON & JOHNSON）2024年第二季度业绩报告（英文版）（23页）.pdf）为本站（liw）主动上传，三个皮匠报告文库仅提供信息存储空间，仅对用户上传内容的表现方式做保护处理，对上载内容本身不做任何修改或编辑。若此文所含内容侵犯了您的版权或隐私，请立即通知三个皮匠报告文库（点击联系客服），我们立即给予删除！

温馨提示：如果因为网速或其他原因下载失败请重新下载，重复下载不扣分。